Advanced Endometrial Cancer Pipeline Summary

DelveInsight’s, “Advanced Endometrial Cancer - Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 26+ pipeline drugs in Advanced Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Endometrial Cancer: Understanding

Advanced Endometrial Cancer: Overview

Metastatic or advanced endometrial cancer is a type of cancer that originated in the lining of the uterus (endometrium) and has spread to distant areas of the body. In general, uterine cancer can metastasize to the rectum or bladder. Other areas where it may spread include the vagina, ovaries and fallopian tubes. This form of cancer is typically slow growing and often detected before it has spread to more distant areas of the body. Different types of treatment are available for patients with endometrial cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials.

Advanced endometrial cancer may present with abnormal vaginal bleeding (especially after menopause), pelvic pain or pressure, and unintentional weight loss. Other symptoms can include pain during intercourse, fatigue, and swelling in the legs if the cancer has spread. As the disease progresses, urinary or bowel issues may also occur. In later stages, metastasis to distant organs such as the lungs or liver can cause additional systemic symptoms.

Risk factors for advanced endometrial cancer include increasing age, obesity, and a history of endometrial hyperplasia or polycystic ovary syndrome (PCOS). Prolonged exposure to estrogen without progesterone such as from hormone replacement therapy or early menarche/late menopause increases risk. Additional factors include diabetes, Lynch syndrome (hereditary nonpolyposis colorectal cancer), and a family history of endometrial or colorectal cancer. A sedentary lifestyle and poor dietary habits may also contribute to increased risk.

Diagnosis of advanced endometrial cancer typically begins with a pelvic examination and imaging studies such as transvaginal ultrasound to assess the uterus. Endometrial biopsy or dilation and curettage (D&C) is performed to confirm malignancy. Further imaging tests like CT, MRI, or PET scans help determine the extent of disease spread. Blood tests, including CA-125 levels, may be used to monitor disease progression. In some cases, diagnostic laparoscopy is employed to evaluate metastasis. Accurate staging is essential to guide treatment planning.

Treatment of advanced endometrial cancer typically involves a combination of therapies. Surgery, such as total hysterectomy with bilateral salpingo-oophorectomy, may be performed if feasible. This is often followed by radiation therapy to control local disease and reduce recurrence. Systemic treatments like chemotherapy commonly using carboplatin and paclitaxel are standard for advanced stages. Hormonal therapy (e.g., progestins or aromatase inhibitors) may be used in hormone receptor-positive tumors. Targeted therapies and immunotherapy (such as PD-1 inhibitors) are emerging options, especially in recurrent or metastatic cases. Treatment plans are tailored based on disease extent, molecular profile, and patient health status.

"Advanced Endometrial Cancer- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Endometrial Cancer pipeline landscape is provided which includes the disease overview and Advanced Endometrial Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Endometrial Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Endometrial Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Endometrial Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Endometrial Cancer.

Advanced Endometrial Cancer Emerging Drugs Chapters

This segment of the Advanced Endometrial Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Endometrial Cancer Emerging Drugs

• PF-08634404: Pfizer

PF-08634404 is an investigational, fully human IgG4 bispecific antibody designed to simultaneously target programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). By blocking the PD-1 immune checkpoint, the antibody restores T-cell-mediated antitumor immune responses, while inhibition of VEGF suppresses tumor angiogenesis, normalizes tumor vasculature, and enhances immune cell infiltration into the tumor microenvironment. This dual mechanism is intended to produce complementary antitumor effects by overcoming immune evasion and reducing the blood supply required for tumor growth and metastasis. Through the combined modulation of immune activation and angiogenesis, the drug has the potential to provide enhanced and durable antitumor activity compared with targeting either pathway alone in advanced endometrial cancer. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Advanced Endometrial Cancer.

• Rinatabart sesutecan: Genmab

Rinatabart sesutecan (Rina-S) is an investigational antibody-drug conjugate (ADC) that selectively targets folate receptor alpha (FR?), a cell surface protein that is frequently overexpressed in endometrial and other gynecologic cancers. The molecule consists of a human IgG1 monoclonal antibody linked via a cleavable hydrophilic linker to the potent topoisomerase I inhibitor exatecan. Upon binding to FR?-expressing tumor cells, the ADC is internalized through endocytosis, where the linker is cleaved to release exatecan intracellularly. The released payload induces DNA damage by inhibiting topoisomerase I, leading to replication stress, apoptosis, and tumor cell death while minimizing exposure to normal tissues. This targeted delivery approach is designed to maximize antitumor efficacy and improve the therapeutic index compared with conventional chemotherapy. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Advanced Endometrial Cancer.

• Retifanlimab: Incyte Corporation/MacroGenics

Retifanlimab (formerly INCMGA0012) is an investigational anti–PD-1 monoclonal antibody developed by Incyte, designed to restore T-cell–mediated immune responses against tumors. It is currently being evaluated for the treatment of advanced or metastatic endometrial cancer, particularly in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Retifanlimab is administered intravenously at a dose of 500 mg every four weeks, with treatment continuing for up to 26 cycles. This therapeutic approach offers a potential new option for patients with advanced endometrial cancer, especially those with limited responses to existing treatments. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Advanced Endometrial Cancer.

• HB0025: Huabo Biopharm Co., Ltd.

HB0025 is an investigational bispecific fusion protein designed to simultaneously target programmed cell death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF), combining immune checkpoint inhibition with anti-angiogenic activity in a single therapeutic agent. By blocking the interaction between PD-L1 and PD-1, HB0025 restores T-cell-mediated antitumor immune responses, while neutralization of VEGF inhibits tumor angiogenesis, reduces abnormal blood vessel formation, and promotes normalization of the tumor vasculature. This dual mechanism enhances immune cell infiltration into the tumor microenvironment while suppressing tumor growth and metastasis. By concurrently targeting immune evasion and angiogenesis, HB0025 is intended to provide synergistic and durable antitumor activity in patients with advanced endometrial cancer. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Advanced Endometrial Cancer.

Further product details are provided in the report……..

Advanced Endometrial Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Endometrial Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Advanced Endometrial Cancer

There are approx. 25+ key companies which are developing the therapies Advanced Endometrial Cancer. The companies which have their Advanced Endometrial Cancer drug candidates in the most advanced stage, i.e. Phase III include, Pfizer and others.

• Phases

DelveInsight’s report covers around 26+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Advanced Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Endometrial Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Endometrial Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Endometrial Cancer drugs.

Advanced Endometrial Cancer Report Insights

• Advanced Endometrial Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Endometrial Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Endometrial Cancer drugs?
• How many Advanced Endometrial Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Endometrial Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Endometrial Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Endometrial Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pfizer
• Genmab
• Incyte Corporation
• MacroGenics
• Huabo Biopharm Co., Ltd.
• BioMimetix JV, LLC.
• Iovance Biotherapeutics, Inc.
• Karyopharm Therapeutics Inc.
• Evergreen Therapeutics, Inc.
• Aadi Bioscience, Inc.
• BioNTech SE

Key Products

• PF-08634404
• Rinatabart sesutecan
• Retifanlimab
• HB0025
• BMX-001 + Paclitaxel
• Lifileucel
• Selinexor
• EG-007
• nab-sirolimus
• BNT329